Custom crystal tombstone commemorating a loan facility for Treasury Wine Estates, an Australian company engaged in grape growing and sourcing, and wine production and marketing. The firm’s brands include Beringer and Penfolds.
(9ALJ153)Custom crystal tombstone commemorating a loan facility for Treasury Wine Estates, an Australian company engaged in grape growing and sourcing, and wine production and marketing. The firm’s brands include Beringer and Penfolds.
(9ALJ153)Curved rectangle tombstone marking the acquisition of SmartEdge, a facility control products and services provider.
(8AMF450)Custom crystal deal toy commemorating the sale of a 50% stake by NYK in its cruise business. The share was acquired by Japanese ship management and investment company Anchor Ship Partners.
(9ALJ130)Car-themed deal tombstone commemorating the acquisition and merger of Jacobs Marketing Group and Dealer 121. JMS is a Long Island-based automotive direct marketing company; Dealer 121 provides a marketing platform tailored for small and medium-sized auto dealerships.
(9AMF142)Custom deal toy marking the acquisition of Portland, Oregon-based online identity management company Janrain. The acquirer was Akamai Technologies, a cybersecurity and content delivery firm headquartered in Cambridge, Massachusetts.
(9ALJ234)Custom crystal deal toy, incorporating a 3-D etch of Mount Fuji and a Merlion, commemorating an investment in fintech-oriented insurance firm Singapore Life. The investment was made by Japan’s Sumitomo Life Insurance Company.
(9ALJ321)Custom crystal tombstone commemorating the provision of $7.8 million in funding for the acquisition of 117 single-family rental units by The Promise Homes Company.
(9AJH021)Custom crystal tombstone commemorating clinical trial financing provided for biopharmaceutical company, Clovis Oncology. The clinical trial sponsored by Clovis involves an ovarian cancer study.
(9ALJ233)Crystal deal toy commemorating a follow-on offering by Gritstone Oncology, a clinical-stage biotechnology firm focused on cancer immunotherapies. Goldman Sachs and Cowen and Company acted as joint book-running managers for the offering.
(9ALJ202)